plitidepsin and Carcinoma--Ehrlich-Tumor

plitidepsin has been researched along with Carcinoma--Ehrlich-Tumor* in 1 studies

Other Studies

1 other study(ies) available for plitidepsin and Carcinoma--Ehrlich-Tumor

Article	Year
Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer letters, 1996, Apr-19, Volume: 102, Issue:1-2 The biological effects of dehydrodidemnin B(DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB). Daily administration of DB or DDB (2.5 micrograms/mouse) almost duplicated the animal life-span and total number of tumour cells decreased by 70-90%. Results suggest a major effect of DDB when administered in the lag phase of growth. DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by DDB-treatment. Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Division; Cell Survival; Depsipeptides; Drug Screening Assays, Antitumor; Enzyme Induction; Mammary Neoplasms, Experimental; Mice; Neoplasm Proteins; Ornithine Decarboxylase; Peptides, Cyclic; Sulfur Radioisotopes; Urochordata	1996

Article

Year

Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates.

Cancer letters, 1996, Apr-19, Volume: 102, Issue:1-2

The biological effects of dehydrodidemnin B(DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB). Daily administration of DB or DDB (2.5 micrograms/mouse) almost duplicated the animal life-span and total number of tumour cells decreased by 70-90%. Results suggest a major effect of DDB when administered in the lag phase of growth. DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by DDB-treatment.

Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Division; Cell Survival; Depsipeptides; Drug Screening Assays, Antitumor; Enzyme Induction; Mammary Neoplasms, Experimental; Mice; Neoplasm Proteins; Ornithine Decarboxylase; Peptides, Cyclic; Sulfur Radioisotopes; Urochordata

1996